Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 45–46
HOS-112168 · Präparat HOS-093615
45 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Prasugrel The mechanism of the interaction is No dose adjustment is needed CYP3A4 inhibition by atazanavir and when prasugrel is or/ritonavir. co-administered with REYATAZ (with or without ritonavir). ANTI-RETROVIRALS Protease inhibitors: The co-administration of REYATAZ/ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors. Therefore, such co- administration is not recommended. Ritonavir 100 mg once daily Atazanavir AUC: ↑250% (↑144% ↑403%)* Ritonavir 100 mg once daily is (atazanavir 300 mg once daily) Atazanavir Cmax: ↑120% (↑56% ↑211%)* used as a booster of atazanavir Atazanavir Cmin: ↑713% (↑359% pharmacokinetics. Studies conducted in HIV- ↑1 339%)* infected patients. *In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n = 33) was compared to atazanavir 400 mg without ritonavir (n = 28).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) prasugrel (HOS-112066) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7d865016f6b42e023e08d8891ed06e591800f50b905c4b971bd44ab2bda40e3c · Zeichen 8288–9918 im Abschnitt